Slowly entering domestic market for new influenza drug Paramivir

On August 10th, a case of H7N9 bird flu infection was diagnosed in Guangdong Province, causing concern for all parties. At present, the first case of H7N9 infection in Guangdong Province indicates that the virus exists in the area. Zhong Nanshan called on the public to reduce contact with birds. If they have experienced flu symptoms in Guangdong, they should use anti-flu drugs within two days.

However, "Daily Economic News" reporter learned that the new anti-influenza drug Palamidi approved in early April this year, the progress of production into the market is still slow. Industry insiders speculated that the "low profile" of South New Drug Kaiba Bio, which has obtained a production license, may be related to the rate of adverse reactions of Palamidi.

Domestic efficacy of new drugs to be tested

On August 10th, Huizhou City, Guangdong Province, was diagnosed with the first case of H7N9 bird flu in the province. It is reported that patients diagnosed in Huizhou are being treated by Zhong Nanshan. Yesterday, relevant staff of the Guangdong Provincial Health Department told the Daily Economic News reporter that the group of experts is stepping up treatment for patients. As of now, the situation of patients has not changed significantly, and individual indicators have improved.

Regarding whether the expert group used paramivir, a new anti-influenza drug, the person said that he did not understand the specific situation.

In response to the H7N9 bird flu epidemic at the beginning of this year, the State Food and Drug Administration opened a "green channel" to accelerate the approval of new anti-influenza drugs. On April 5, the Food and Drug Administration issued an announcement saying that it has approved the new anti-influenza drug salamivir sodium chloride injection (hereinafter referred to as paramefate), Hunan Nonferrous Metals Group's Hunan Nonferrous Carbome Bio-Pharmaceutical Co., Ltd. and Guangzhou South New Pharmaceutical Co., Ltd. got a production license.

From the point of view of the company's production capacity, Palamidi takes only one day from the start of the production to the production, plus 14 days of fungal inspection, and the total production time is 15 days. Nanxin Pharmaceutical has a large infusion production line that can produce 30,000 bottles of peramivir daily.

It stands to reason that raw materials, production lines, and approvals are all available, and the new drug, Palamidi, is just around the corner. However, "Daily Economic News" reporter interviewed a number of Nanxin pharmaceutical agents found that now Paramivir can be described as "only heard of its voice."

A regional manager told reporters that the factory is now in stock and can be contacted directly if needed. "It hasn't started selling yet. It's just that there are goods in the factory. The specific sales situation will only be known to the factory."